E) Macrolides are the treatment of choice - THIS IS INCORRECT
Macrolides are NOT the treatment of choice for S. aureus infections. The correct first-line antibiotics for S. aureus bacteremia are vancomycin or daptomycin for empiric coverage (which covers MRSA), followed by cefazolin or antistaphylococcal penicillins (like oxacillin or nafcillin) once methicillin-susceptible S. aureus (MSSA) is confirmed 1. Macrolides have no role as first-line therapy for serious staphylococcal infections.
Why the Other Statements Are CORRECT:
A) Soft Tissue Infections - TRUE
S. aureus is indeed the most common cause of purulent skin and soft tissue infections 2. This is a well-established clinical fact, with many strains being methicillin-resistant, requiring empiric MRSA coverage 2.
B) Endocarditis Screening in Persistent Bacteremia - TRUE
All patients with S. aureus bacteremia should undergo transthoracic echocardiography, and transesophageal echocardiography is mandatory for those with persistent bacteremia (≥48 hours), persistent fever, metastatic infection foci, or implantable cardiac devices 1. Prolonged bacteremia (≥48 hours) carries a 90-day mortality risk of 39%, and approximately 12% of S. aureus bacteremia cases develop endocarditis 1.
C) Toxic Shock - TRUE
S. aureus produces superantigens including toxic shock syndrome toxin-1 (TSST-1), which causes toxic shock syndrome 3. This is a well-documented pathogenic mechanism of the organism.
D) Osteomyelitis - TRUE
S. aureus is a common cause of osteomyelitis, including vertebral osteomyelitis (approximately 4% of bacteremia cases) 1, 4. The bacterium causes metastatic infection in more than one-third of bacteremia cases, with bone and joint involvement being frequent 1.
Key Treatment Principles:
For empiric therapy: Start vancomycin or daptomycin to cover MRSA 1
Once susceptibilities are known:
- MSSA: Switch to cefazolin or antistaphylococcal penicillins (oxacillin, nafcillin) 1, 4
- MRSA: Continue vancomycin, daptomycin, or use ceftobiprole 1
Agents NOT recommended as first-line: Linezolid and trimethoprim-sulfamethoxazole lack robust clinical trial data for bacteremia and should not be used as first-line treatment 5. Macrolides are not mentioned in any contemporary guidelines for serious S. aureus infections.